Todd Braciak is a co-founder of Kosmas Therapeutics and worked with the company in the early development and testing of its pilot drug KT-1 for the treatment of AML. He was also a staff scientist at the Klinikum der Universität München, where he studied the ability of the molecule to recruit NK cells and target the molecules CD33 and CD123 on leukemia stem cells.

Todd performed pioneering studies using a recombinant adenovirus expressing the cytokine interleukin-12 that exclusively recruited NK cells in the treatment of experimental solid prostate cancers. This work offered early evidence that defects in components of the antigen-processing machinery evolve in many cancers, which will therefore benefit from a combination treatment with agents such as KT-1. This is the case particularly for cancers that have lost MHC and the ability to be recognized by T cell response.

Todd had previously worked for over 15 years with one of the most highly esteemed immunologists in the world, Dr. Eli Sercarz. This position started as a post doc at UCLA with Dr. Sercaz and continued at the La Jolla Institute for Allergy and Immunology.  Before moving on to working with AML and KT1, he was an Assistant Member in his team at the Torrey Pines Institute for Molecular Studies in San Diego, CA .

Todd received his PhD in Medical Sciences from McMaster University in Ontario, Canada, as well as his BS in Biochemistry from Michigan State University.